



ATTORNEY DOCKET NO: 0264724-0031

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Barry S. Fogel
Appl. No. : 09/893,244
Filed : June 27, 2001
For : Methods of Treating Tardive Dyskinesia and Other Movement Disorders

Assistant Commissioner of Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Under 35 USC 120, this application relies on the earlier filing date of application serial number 09/193,892, filed on November 18, 1998. The following references were submitted to and/or cited by the Office in the prior utility application and, therefore, are not provided in this application:

4,122,193	Scherm et al.	October 24, 1978
4,233,229	Chakrabarti	November 11, 1980
4,355,043	Durlach	October 19, 1982
5,061,703	Bormann et al.	October 29, 1991
5,262,162	Bormann et al.	November 16, 1993
5,382,601	Nürnberg et al.	January 17, 1995
5,455,279	Lipton	October 3, 1995
5,602,150	Lidsky	February 11, 1997
5,614,560	Lipton	March 25, 1997

Alexander, et al., "Serum Calcium and Magnesium in Schizophrenia: Relationship to Clinical Phenomena and Neuroleptic Treatment", Brit. F. Psychiat. 133: 143-49, 1978.

1617 #3
RECEIVED
OCT 03 2001
TECH CENTER 1600/2900
M.M.
10/4/01

Ananth, et al., "Meige's Syndrome Associated with Neuroleptic Treatment", Am J. Psychiatry 145:4, April, 1988.

Andrew, "Clinical Relationship of Extrapyrimal Symptoms and Tardive Dyskinesia", Can. J. Psych., 39:576-580, 1994.

Andreassen, et al., "Tardive Dyskinesia: Behavioral Effects of Repeated Intracerebroventricular Haloperidol Injections in Rats Do Not Confirm the Kindling Hypothesis", Pharmacology Biochemistry and Behavior, 49:2, 309-312, 1994

Andreassen, et al., "Inhibition by Memantine of the Development of Persistent Oral Dyskinesias Induced by Long-Term Haloperidol Treatment of Rats", British Journal of Pharmacology 119: 751-757, 1996.

Arthurs, et al., "Treatment of Blepharospasm with Medication, Surgery and Type A Botulinum Toxin", Can J. Ophthalmol, 22:1, 1987.

Athanassenas, et al., "Serum Calcium and Magnesium Levels in Chronic Schizophrenics", Journal of Clinical Psychopharmacology, 3:4, August, 1983

Bezchilbynk-Butler et al., "Antiparkinsonian Drugs in the Treatment of Neuroleptic-Induced Extrapyrimal Symptoms", Can. J. Psych., 39:74-84, 1994.

Boumans et al., "Is the Social Acceptability of Psychiatric Patients Decreased by Orofacial Dyskinesia?", Schizo Bull, 20:339-344, 1994.

Britton, et al., "Dextromethorphan Protects Against Cerebral Injury Following Transient, But Not Permanent, Focal Ischemia in Rats" Life Sciences, 60:20, 1729-1740, 1997.

Büchel et al., "Oral Tardive Dyskinesia: Validation of a Measuring Device Using Digital Image Processing", Psychopharmacology-Berl, 117:162-165, 1995.

Casey, D. "Pharmacology of Blepharospasm-Oromandibular Dystonia Syndrome", *Neurology*, 30:690-695, July, 1980.

Cassady, et al., "Neuroleptic Induced Movement Disorders", Cambridge, England: Cambridge University Press, 1997, pp454-469.

Chabenat, et al., " Physicochemical, Pharmacological and Pharmacokinetic Study of a New GABAergic Compound, Calcium Acetylhomotaurinate", *Methods Find Exp Clin Pharmacol*, 10:311-7, 1988 May.

Chakos et al., "Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia", *Arch Gen Psychiatry*, 53:313-319, 1996.

Chappell, et al., "Future Therapies of Tourette Syndrome", *Neurologic Clinics of North America*, 15:2, May, 1997.

Chen, et al., "Focal Dystonia and Repetitive Motion Disorders", *Clinical Orthopaedics and Related Research*, 351: 102-106.

Dabiri, et al., "Effectiveness of Vitamin E for Treatment of Long-Term Tardive Dyskinesia", *Am J. Psychiatry* 151:6, June 1994.

Decker et al., "Amantadine Hydrochloride Treatment of Tardive Dyskinesia", October 7, *New England J. Med*, 285:860, 1971.

Delfs et al., "Expression of Glutamic Acid Decarboxylase mRNA in Striatum and Pallidum in an Animal Model of Tardive Dyskinesia", *Exp. Neurol*, 133:175-188, 1995.

De Mattos, et al., "Distonias Aspectos Clinicose E Terapeuticos EM 64 Pacientes", *Arq. Neuropsiquiatr*, 54:30-36, 1996.

Dimpfel, "Effects of Memantine on Synaptic Transmission in the Hippocampus in Vitro", *Arzneimittelforschung*, 45:1-5, 1995.

Durlach, et al., "Magnesium Status and Ageing: An Update", Magnesium Research 11:25-42, 1997.

Egan M.F., et al., "Treatment of Tardive Dyskinesia" Schizophr Bull, 23(4):583-609 1997

Elston, J. "The Management of Blepharospasm and Hemifacial Spasm", J. Neurol 239:5-8, 1992.

Ema, et al., "Alcohol-Induced Vascular Damage of Brain is Ameliorated by Administration of Magnesium", Alcohol, 15:95-103, 1998.

Erdo et al., "Memantine is Highly Potent in Protecting Cortical Cultures against Excitotoxic Cell Death Evoked by Glutamate and N-Methyl-D-Aspartate", Eur. J. Pharmacol, 198:215-217, 1991.

Esper, et al., "Adult-Onset Focal Dystonias: Presentation and Treatment Options", Tennessee Medicine, 18-20, January, 1997.

Fariello, R.G. et al., "Homotaurine (3 Aminopropanesulfonic Acid; 3APS) Protects From The Convulsant and Cytotoxic Effect of Systemically Administered Kainic Acid." Neurology, 32:241-5, March, 1982.

Galardi, et al., "Basal Ganglia and Thalamo-Cortical Hypermetabolism in Patients with Spasmodic Torticollis", Acta Neurol Scand 94:172-176, 1996.

Greensmith, et al., "Magnesium Ions Reduce Motoneuron Death Following Nerve Injury or Exposure to N-Methyl-D-Aspartate In The Developing Rat

Gao et al., "Tiagabine Inhibits Haloperidol-Induced Oral Dyskinesias in Rats", J. Neural Transmission, 95:63-69, 1994.

Gardos, et al., "The Treatment of Tardive Dyskinesias", Psychopharmacology, 1503-1511, 1995.

Gullestad, et al., "Magnesium Status in Healthy Free-Living Elderly Norwegians", Journal of the American College of Nutrition, 13:1,45-50.

Hallett, M. "The Neurophysiology of Dystonia", Arch Neurol, 55: May, 1998

Hayashi et al., "Prevalence of and Risk Factors for Respiratory Dyskinesia", Clin. Neuropharmacol, 19:390-398, 1996.

Holds, et al., "Facial Dystonia, Essential Blepharospasm and Hemifacial Spasm", AFP, 43(6): 2113-2120, June, 1991.

Imamura et al., "Improved Presevation with Amantadine", Abstract, No-To-Shinkei, 46:556-562, 1994.

Jacoby, et al., "Diltiazem Reduces the Contractility of Extraocular Muscles in Vitro and in Vivo", Investigative Ophthalmology & Visual Science, 31:569-576, March, 1990.

Jankovic, J. "Treatment of Hyperkinetic Movement Disorders with Tetrabenazine: A Double-Blind Crossover Study", Ann Neurol 11:41-47, 1982.

Jankovic, J. "Blepharospasm and Orofacial - Cervical Dystonia: Clinical and Pharmacological Findings in 100 Patients", Ann Neurol 13:402-411, 1983.

Jeste et al., "Risk of Tardive Dyskinesia in Older Patients. A Prospective Longitudinal Study of 266 Outpatients", Arch Gen Psychiatry, 52:756-765, 1995.

Keilhoff et al., "Memantine Prevents Quinolinic Acid-Induced Hippocampal Damage", Eur. J. Pharmacol, 219:451-454, 1992.

Kirov, et al., "Plasma Magnesium Levels in a Population of Psychiatric Patients: Correlations with Symptoms", Neuropsychobiology 30:73-78, 1994.

Kornhuber et al., "New Therapeutic Possibilities with Low-Affinity NMDA Receptor Antagonists", Abstract, Nervenarzt, 67:77-82, 1996.

Krieglstein, et al., "Apparent Independent Action of Nimodipine and Glutamate Antagonists to Protect Cultured Neurons Against Glutamate-Induced Damage

Kurata, et al., "Meige's Syndrome During Long-Term Neuroleptic Treatment", The Japanese Journal of Psychiatry 43: 627-631, 1989.

Kurlan, R. "Treatment of Tics", Neurologic Clinics of North America, 15:2, 403-409, May, 1997.

Lam et al., "Vitamin E in the Treatment of Tardive Dyskinesia: A Replication Study, J. Nerv. Ment Dis, 182:113-114, 1994.

Latimer, "Tardive Dyskinesia: A Review", Abstract, Can J. Psych, 40:S49-54, 1995.

Leckman, et al., "Tic Disorders", The Psychiatric Clinics of North America, 20:4 839-861, December, 1997.

Lichter, et al., "Predictors of Clonidine Response in Tourette Syndrome: Implications and Inferences", Journal of Child Neurology 11:93-97, March, 1996.

Lipski, et al., "A Study of Nutritional Deficits of Long-Stay Geriatric Patients, Age and Ageing 22:244-255, 1993.

Lohr et al., "A Double-Blind Placebo-Controlled Study of Vitamin E Treatment of Tardive Dyskinesia", J. Clin. Psychiatry, 57:167-173, 1996.

Lombardini, John B. "Opposite Effects of 2-Aminoethanesulfonic Acid (Taurine) and Aminomethanesulfonic Acid on Calcium Ion Uptake in Rat Retinal Preparations"

Martin, et al., "Comparison of Inorganic Elements from Autopsy Tissue of Young and Elderly Subjects", J. Trace Elem. Electrolytes Health Dis.,5:203-211, 1991.

Mauriello, et al., "Treatment Selections of 239 Patients with Blepharospasm and Meige Syndrome over 11 Years", Br. J. Ophthalmol, 80(12):1073-1076, December, 1996

Mauriello, et al., "Treatment Choices of 119 Patients with Hemifacial Spasm over 11 Years", Clinical Neurology and Neurosurgery, 98: 213-216, August 1996.

Meshul, et al., "Correlation of Vacuous Chewing Movements with Morphological Changes in Rats Following 1-Year Treatment with Haloperidol", *Psychopharmacology* 125:238-247, 1996

Micheli, et al., "Continuous Dopaminergic Stimulation in Cranial Dystonia", *Clinical Neuropharmacology*, 11:3, 241-249.

Muller et al., "Noncompetitive NMDA Receptor Antagonists with Fast Open-Channel Blocking Kinetics and Strong Voltage-Dependency as Potential Therapeutic Agents for Alzheimer's Dementia", *Pharmacopsychiatry*, 28:113-124, 1995.

Pahl et al., "Positron-Emission Tomography in Tardive Dyskinesia", *J. Neuropsych Clin. Neurosci*, 7:457-465, 1995.

Panula-Lehto E. et al., "Effects of Taurine, Homotaurine and GABA on Hypothalamic and Striatal dopamine Metabolism." *Naunyn Schmiedeberg's Arch Pharmacol*, 346:57-62, July, 1992

Perlmutter, et al., "Decreased [^{18}F] Spiperone Binding in Putamen Idiopathic Focal Dystonia", *The Journal of Neuroscience*, 17:843-850, 1997.

Ploceniak, "Bruxisme et magnesium, mon experience clinique depuis 1980" *Communications Libres*, 91, supplII, 1990

Raja, "The Treatment of Tardive Dyskinesia", Abstract, *Schweiz Arch Neurol Psychiatr*, 47: 1996.

Ransmayr, et al., "Pharmacological Study in Meige's Syndrome with Predominant Blepharospasm", *Clinical Neuropharmacology*, 11:68-76, 1988.

Rouhani, S. et al., "Effects of Muscimol or Homotaurine on Sleep-Wake States in Alcohol-dependent rats during Withdrawal." *Pharmacol Biochem Behav*, 59:955-60, April, 1998

Sachdev, "Blinking-blepharospasm after long-term neuroleptic treatment", *The Medical Journal of Australia*, 150:341-343, March 20, 1989

Sachdev et al., "Negative Symptoms, Cognitive Dysfunction, Tardive Akathisia and Tardive Dyskinesia", *Acta Psychiatr Scand*, 93:451-459, 1996.

Sanberg, et al., "Nicotine for the Treatment of Tourette's Syndrome", *Pharmacol. Ther.* Vol. 74, 21-25, 1997.

Sandyk, "Blepharospasm - Successful Treatment with Baclofen and Sodium Valproate", *SA Medical Journal*, 64:3 December, 1993.

Sano et al., "A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease", *The New England Journal of Medicine*, Vol. 336, No. 17, pp. 1216-1247, April 24, 1997.

Scahill, et al., "Fluoxetine Has No Marked Effect on Tic Symptoms in Patients with Tourette's Syndrome: A Double-Blind Placebo-Controlled Study," *Journal of Child and Adolescent Psychopharmacology*, 7:75-85, 1997.

Schulz et al., "Neuroprotective Strategies for Treatment of Lesions Produced by Mitochondrial Toxins: Implications for Neurodegenerative Diseases", *Neuroscience*, 71:1043-1048, 1996.

Shane, et al., "Magnesium Deficiency in Alcohol Addiction and Withdrawal", *Magnes Trace Elem*, 92:263-268, 1991.

Silver et al., "No Difference in the Effect of Biperiden and Amantadine on Parkinsonian- and Tardive Dyskinesia-type Involuntary Movements: A Double-Blind Crossover, Placebo-Controlled Study in Medicated Chronic Schizophrenic Patients", *Abstract, J. Clin. Psychiatry*, 56:167-170, 1995.

Silver, et al., "Case Study: Long-Term Potentiation of Neuroleptics with Transdermal Nicotine in Tourette's Syndrome, *J. Am. Chil. Adolesc. Psychiatry*, 35:12, December, 1996

Stoessl, "Effects of Ethanol in a Putative Rodent Model of Tardive Dyskinesia", *Pharmacol Biochem Behav*, 54:541-546, 1996.

Steingard, "Adjunctive Clonazepam Treatment of Tic Symptoms in Children with Comorbid Tic Disorders and ADHD", *J. Am. Acad. Child Adolesc. Psychiatry*, 33:3, March/April, 1994

Swartz, "Tardive Psychopathology", *Neuropsychobiology*, 43:115-119, 1995.

Tirelli et al., "Differential Effects of Direct and Indirect Dopamine Agonists on the Induction of Gnawing in C57B1/6J Mice", *J. Pharmacol Exp. Ther.*, 273:7-15, 1995.

Trube, et al., "Dextromethorphan: Cellular Effects Reducing Neuronal Hyperactivity" *Epilepsia*. 35:5 S62-S67, 1994

Tsai, et al., "Markers of Glutamatergic Neurotransmission and Oxidative Stress Associated with Tardive Dyskinesia", *Am J. Psychiatry* 155:9, September, 1998.

Vale et al., "Amantadine for Dyskinesia Tarda", *New Eng. J. Med.*, 284:673, 1971.

Van-Rekum et al., "N of 1 Study: Amantadine for the Amotivational Syndrome in a Patient with Traumatic Brain Injury", *Brian Inj.* 9:49-53, 1995.

Waddington et al., "Cognitive Dysfunction in Chronic Schizophrenia Followed Prospectively Over 10 Years and Its Longitudinal Relationship to the Emergence of Tardive Dyskinesia", *Psychol Med*, 26:681-688, 1996.

Wenk et al., "MK-801, Memantine and Amantadine Show Neuroprotective Activity in the Nucleus Basalis Magnocellularis", *Eur. J. Pharmacol*, 293:267-270, 1995.

Wilde, et al., "Acamprosate", *Adis Drug Evaluation*, 53:1038-1053, June, 1997.


Yassa, et al., "Plasma Magnesium in Chronic Schizophrenia", *Int. Pharmacopsychiat.* 14:57-64 (1979)

Ziemann, et al., "Decreased Motor Inhibition in Tourette's Disorder: Evidence From Transcranial Magnetic Stimulation", Am J Psychiatry, 154:1277-1284, 1997.

This statement is being filed within three months of the filing date of the application. If there are any other charges, or any credits, please apply them to Deposit Account No. 03-1721.


Respectfully submitted,

Date: 9/25/07




Sam Pasternack
Reg. No. 29,576

CHOATE, HALL & STEWART
EXCHANGE PLACE
53 STATE STREET
BOSTON, MASSACHUSETTS 02109-2891
TELEPHONE (617) 248-5000
FACSIMILE (617) 248-4000
3314648_1.DOC

I hereby certify that this correspondence is being deposited with the United States Postal service as first class mail in an envelope addressed to: Assistant Commissioner For Patents, Washington, D.C. 20231
on September 25, 2007


Form PTO-144
(REV. 8-83)



U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket:
0264724-0007

In re Application No.
09/193,892

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant: Fogel

Filing Date:
November 18, 1998

Group: 1614

U. S. PATENT DOCUMENTS

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
	4,122,193	Scherm et al.	October 24, 1978		
	4,233,229	Chakrabarti	November 11, 1980		
	4,355,043	Durlach	October 19, 1982		
	5,061,703	Bormann et al.	October 29, 1991		
	5,262,162	Bormann et al.	November 16, 1993		
	5,382,601	Nürnberg et al.	January 17, 1995		
	5,455,279	Lipton	October 3, 1995		
	5,602,150	Lidsky	February 11, 1997		
	5,614,560	Lipton	March 25, 1997		


RECEIVED
 OCT 03 2001
 TECH CENTER 1500/2900

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Alexander, et al., "Serum Calcium and Magnesium in Schizophrenia: Relationship to Clinical Phenomena and Neuroleptic Treatment", Brit. F. Psychiat. 133: 143-49, 1978.
	Ananth, et al., "Meige's Syndrome Associated with Neuroleptic Treatment", Am J. Psychiatry 145:4, April, 1988.

Form PTO-1449
(REV. 8-83)



U.S. Department of Commerce
Patent and Trademark Office

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Atty. Docket:
0264724-0007

In re Application No.
09/193,892

Applicant: Fogel

Filing Date:
November 18, 1998

Group: 16

RECEIVED
OCT 03 2001
TECH CENTER 1600/2900

Andrew, "Clinical Relationship of Extrapyrimal Symptoms and Tardive Dyskinesia", Can. J. Psych., 39:576-580, 1994.

Andreassen, et al., "Tardive Dyskinesia: Behavioral Effects of Repeated Intracerebroventricular Haloperidol Injections in Rats Do Not Confirm the Kindling Hypothesis", Pharmacology Biochemistry and Behavior, 49:2, 309-312, 1994

Andreassen, et al., "Inhibition by Memantine of the Development of Persistent Oral Dyskinesias Induced by Long-Term Haloperidol Treatment of Rats", British Journal of Pharmacology 119: 751-757, 1996.

Arthurs, et al., "Treatment of Blepharospasm with Medication, Surgery and Type A Botulinum Toxin", Can J. Ophthalmol, 22:1, 1987.

Athanassenas, et al., "Serum Calcium and Magnesium Levels in Chronic Schizophrenics", Journal of Clinical Psychopharmacology, 3:4, August, 1983

Bezchilbynk-Butler et al., "Antiparkinsonian Drugs in the Treatment of Neuroleptic-Induced Extrapyrimal Symptoms", Can. J. Psych., 39:74-84, 1994.

Boumans et al., "Is the Social Acceptability of Psychiatric Patients Decreased by Orofacial Dyskinesia?", Schizo Bull, 20:339-344, 1994.

Britton, et al., "Dextromethorphan Protects Against Cerebral Injury Following Transient, But Not Permanent, Focal Ischemia in Rats" Life Sciences, 60:20, 1729-1740, 1997.

Büchel et al., "Oral Tardive Dyskinesia: Validation of a Measuring Device Using Digital Image Processing", Psychopharmacology-Berl, 117:162-165, 1995.

Casey, D. "Pharmacology of Blepharospasm-Oromandibular Dystonia Syndrome", Neurology, 30:690-695, July, 1980.

Cassady, et al., "Neuroleptic Induced Movement Disorders", Cambridge, England: Cambridge University Press, 1997, pp454-469.

Chabenat, et al., " Physicochemical, Pharmacological and Pharmacokinetic Study of a New GABAergic Compound, Calcium Acetylhomotaurinate", Methods Find Exp Clin Pharmacol, 10:311-7, 1988 May.

Chakos et al., "Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia", Arch Gen Psychiatry, 53:313-319, 1996.

Chappell, et al., "Future Therapies of Tourette Syndrome", Neurologic Clinics of North America, 15:2, May, 1997.

Chen, et al., "Focal Dystonia and Repetitive Motion Disorders", Clinical Orthopaedics and Related Research", 351: 102-106.

Form PTO-1449
(REV. 8-83)


U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket:
0264724-0007

In re Application No.
09/193,897

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

(Use several sheets if necessary)



Applicant: Fogel

Filing Date:
November 18, 1998

Group: 1600/2900

RECEIVED
OCT 03 2001
TECH CENTER 1600/2900

Dabiri, et al., "Effectiveness of Vitamin E for Treatment of Long-Term Tardive Dyskinesia", Am J. Psychiatry 151:6, June 1994.

Decker et al., "Amantadine Hydrochloride Treatment of Tardive Dyskinesia", October 7, New England J. Med, 285:860, 1971.

Delfs et al., "Expression of Glutamic Acid Decarboxylase mRNA in Striatum and Pallidum in an Animal Model of Tardive Dyskinesia", Exp. Neurol, 133:175-188, 1995.

De Mattos, et al., "Distonias Aspectos Clinicose E Terapeuticos EM 64 Pacientes", Arq. Neuropsiquiatr, 54:30-36, 1996.

Dimpfel, "Effects of Memantine on Synaptic Transmission in the Hippocampus in Vitro", Arzneimittelforschung, 45:1-5, 1995.

Durlach, et al., "Magnesium Status and Ageing: An Update", Magnesium Research 11:25-42, 1997.

Egan M.F., et al., "Treatment of Tardive Dyskinesia" Schizophr Bull, 23(4):583-609 1997

Elston, J. "The Management of Blepharospasm and Hemifacial Spasm", J. Neurol 239:5-8, 1992.

Ema, et al., "Alcohol-Induced Vascular Damage of Brain is Ameliorated by Administration of Magnesium", Alcohol, 15:95-103, 1998.

Erdo et al., "Memantine is Highly Potent in Protecting Cortical Cultures against Excitotoxic Cell Death Evoked by Glutamate and N-Methyl-D-Aspartate", Eur. J. Pharmacol, 198:215-217, 1991.

Esper, et al., "Adult-Onset Focal Dystonias: Presentation and Treatment Options", Tennessee Medicine, 18-20, January, 1997.

Fariello, R.G. et al., "Homotaurine (3 Aminopropanesulfonic Acid; 3APS) Protects From The Convulsant and Cytotoxic Effect of Systemically Administered Kainic Acid." Neurology, 32:241-5, March, 1982.

Galardi, et al., "Basal Ganglia and Thalamo-Cortical Hypermetabolism in Patients with Spasmodic Torticollis", Acta Neurol Scand 94:172-176, 1996.

Greensmith, et al., "Magnesium Ions Reduce Motoneuron Death Following Nerve Injury or Exposure to N-Methyl-D-Aspartate In The Developing Rat

Gao et al., "Tiagabine Inhibits Haloperidol-Induced Oral Dyskinesias in Rats", J. Neural Transmission, 95:63-69, 1994.

Gardos, et al., "The Treatment of Tardive Dyskinesias", Psychopharmacology, 1503-1511, 1995.

Form PTO-1449
(REV. 8-83)


U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket:
0264724-0007

In re Application No.
09/193,892

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

(Use several sheets if necessary)



Applicant: Fogel

Filing Date:
November 18, 1998

Group: 16

RECEIVED
OCT 03 2001
TECH CENTER 1600-2900

Gullestad, et al., "Magnesium Status in Healthy Free-Living Elderly Norwegians", Journal of the American College of Nutrition, 13:1,45-50.

Hallett, M. "The Neurophysiology of Dystonia", Arch Neurol, 55: May, 1998

Hayashi et al., "Prevalence of and Risk Factors for Respiratory Dyskinesia", Clin. Neuropharmacol, 19:390-398, 1996.

Holds, et al., "Facial Dystonia, Essential Blepharospasm and Hemifacial Spasm", AFP, 43(6): 2113-2120, June, 1991.

Imamura et al., "Improved Presevation with Amantadine", Abstract, No-To-Shinkei, 46:556-562, 1994.

Jacoby, et al., "Diltiazem Reduces the Contractility of Extraocular Muscles in Vitro and in Vivo", Investigative Ophthalmology & Visual Science, 31:569-576, March, 1990.

Jankovic, J. "Treatment of Hyperkinetic Movement Disorders with Tetrabenazine: A Double-Blind Crossover Study", Ann Neurol 11:41-47, 1982.

Jankovic, J. "Blepharospasm and Orofacial - Cervical Dystonia: Clinical and Pharmacological Findings in 100 Patients", Ann Neurol 13:402-411, 1983.

Jeste et al., "Risk of Tardive Dyskinesia in Older Patients. A Prospective Longitudinal Study of 266 Outpatients", Arch Gen Psychiatry, 52:756-765, 1995.

Keilhoff et al., "Memantine Prevents Quinolinic Acid-Induced Hippocampal Damage", Eur. J. Pharmacol, 219:451-454, 1992.

Kirov, et al., "Plasma Magnesium Levels in a Population of Psychiatric Patients: Correlations with Symptoms", Neuropsychobiology 30:73-78, 1994.

Kornhuber et al., "New Therapeutic Possibilities with Low-Affinity NMDA Receptor Antagonists", Abstract, Nervenarzt, 67:77-82, 1996.

Krieglstein, et al., "Apparent Independent Action of Nimodipine and Glutamate Antagonists to Protect Cultured Neurons Against Glutamate-Induced Damage

Kurata, et al., "Meige's Syndrome During Long-Term Neuroleptic Treatment", The Japanese Journal of Psychiatry 43: 627-631, 1989.

Kurlan, R. "Treatment of Tics", Neurologic Clinics of North America, 15:2, 403-409, May, 1997.

Lam et al., "Vitamin E in the Treatment of Tardive Dyskinesia: A Replication Study, J. Nerv. Ment Dis, 182:113-114, 1994.

Latimer, "Tardive Dyskinesia: A Review", Abstract, Can J. Psych, 40:S49-54, 1995.

Form PTO-1449
(REV. 8-83)

U.S. Department of Commerce
Patent and Trademark Office

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Atty. Docket:
0264724-0007

In re Application No.
09/193,892

Applicant: Fogel

Filing Date:
November 18, 1998

Group: 161

TECH CENTER 1600-2900

OCT 03 2001

RECEIVED

Leckman, et al., "Tic Disorders", The Psychiatric Clinics of North America, 20:4 839-861, December, 1997.

Lichter, et al., "Predictors of Clonidine Response in Tourette Syndrome: Implications and Inferences", Journal of Child Neurology 11:93-97, March, 1996.

Lipski, et al., "A Study of Nutritional Deficits of Long-Stay Geriatric Patients, Age and Ageing 22:244-255, 1993.

Lohr et al., "A Double-Blind Placebo-Controlled Study of Vitamin E Treatment of Tardive Dyskinesia", J. Clin. Psychiatry, 57:167-173, 1996.

Lombardini, John B. "Opposite Effects of 2-Aminoethanesulfonic Acid (Taurine) and Aminomethanesulfonic Acid on Calcium Ion Uptake in Rat Retinal Preparations"

Martin, et al., "Comparison of Inorganic Elements from Autopsy Tissue of Young and Elderly Subjects", J. Trace Elem. Electrolytes Health Dis., 5:203-211, 1991.

Mauriello, et al., "Treatment Selections of 239 Patients with Blepharospasm and Meige Syndrome over 11 Years", Br. J. Ophthalmol, 80(12):1073-1076, December, 1996

Mauriello, et al., "Treatment Choices of 119 Patients with Hemifacial Spasm over 11 Years", Clinical Neurology and Neurosurgery, 98: 213-216, August 1996.

Meshul, et al., "Correlation of Vacuous Chewing Movements with Morphological Changes in Rats Following 1-Year Treatment with Haloperidol", Psychopharmacology 125:238-247, 1996

Micheli, et al., "Continuous Dopaminergic Stimulation in Cranial Dystonia", Clinical Neuropharmacology, 11:3, 241-249.

Muller et al., "Noncompetitive NMDA Receptor Antagonists with Fast Open-Channel Blocking Kinetics and Strong Voltage-Dependency as Potential Therapeutic Agents for Alzheimer's Dementia", Pharmacopsychiatry, 28:113-124, 1995.

Pahl et al., "Positron-Emission Tomography in Tardive Dyskinesia", J. Neuropsych Clin. Neurosci, 7:457-465, 1995.

Panula-Lehto E. et al., "Effects of Taurine, Homotaurine and GABA on Hypothalamic and Striatal dopamine Metabolism." Naunyn Schmiedebergs Arch Pharmacol, 346:57-62, July, 1992

Perlmutter, et al., "Decreased [¹⁸F] Spiperone Binding in Putamen Idiopathic Focal Dystonia", The Journal of Neuroscience, 17:843-850, 1997.

Ploceniak, "Bruxisme et magnesium, mon experience clinique depuis 1980" Communications Libres, 91, supplII, 1990

Form PTO-1449
(REV. 8-83)


U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket:
0264724-0007

In re Application No.
09/193,892

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

(Use several sheets if necessary)



Applicant: Fogel

Filing Date:
November 18, 1998

Group: 161

RECEIVED
OCT 03 2001
TECH CENTER 1600/2900

Raja, "The Treatment of Tardive Dyskinesia", Abstract, Schweiz Arch Neurol Psychiatr, 47: 1996.

Ransmayr, et al., "Pharmacological Study in Meige's Syndrome with Predominant Blepharospasm", Clinical Neuropharmacology, 11:68-76, 1988.

Rouhani, S. et al., "Effects of Muscimol or Homotaurine on Sleep-Wake States in Alcohol-dependent rats during Withdrawal." Pharmacol Biochem Behav, 59:955-60, April, 1998

Sachdev, "Blinking-blepharospasm after long-term neuroleptic treatment", The Medical Journal of Australia, 150:341-343, March 20, 1989

Sachdev et al., "Negative Symptoms, Cognitive Dysfunction, Tardive Akathisia and Tardive Dyskinesia", Acta Psychiatr Scand, 93:451-459, 1996.

Sanberg, et al., "Nicotine for the Treatment of Tourette's Syndrome", Pharmacol. Ther. Vol. 74, 21-25, 1997.

Sandyk, "Blepharospasm - Successful Treatment with Baclofen and Sodium Valproate", SA Medical Journal, 64:3 December, 1993.

Sano et al., "A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease", The New England Journal of Medicine, Vol. 336, No. 17, pp. 1216-1247, April 24, 1997.

Scahill, et al., "Fluoxetine Has No Marked Effect on Tic Symptoms in Patients with Tourette's Syndrome: A Double-Blind Placebo-Controlled Study," Journal of Child and Adolescent Psychopharmacology, 7:75-85, 1997.

Schulz et al., "Neuroprotective Strategies for Treatment of Lesions Produced by Mitochondrial Toxins: Implications for Neurodegenerative Diseases", Neuroscience, 71:1043-1048, 1996.

Shane, et al., "Magnesium Deficiency in Alcohol Addiction and Withdrawal", Magnes Trace Elem, 92:263-268, 1991.

Silver et al., "No Difference in the Effect of Biperiden and Amantadine on Parkinsonian- and Tardive Dyskinesia-type Involuntary Movements: A Double-Blind Crossover, Placebo-Controlled Study in Medicated Chronic Schizophrenic Patients", Abstract, J. Clin. Psychiatry, 56:167-170, 1995.

Silver, et al., "Case Study: Long-Term Potentiation of Neuroleptics with Transdermal Nicotine in Tourette's Syndrome, J. Am. Chil. Adolesc. Psychiatry, 35:12, December, 1996

Stoessl, "Effects of Ethanol in a Putative Rodent Model of Tardive Dyskinesia", Pharmacol Biochem Behav, 54:541-546, 1996.

Form PTO-1449
(REV. 8-83)


U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket:
0264724-0007

In re Application No.
09/193,892

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

(Use several sheets if necessary)



Applicant: Fogel

Filing Date:
November 18, 1998

Group: 1

RECEIVED
OCT 03 2001
TTC CENTER 1600 2900

Steingard, "Adjunctive Clonazepam Treatment of Tic Symptoms in Children with Comorbid Tic Disorders and ADHD, J. Am. Acad. Child Adolesc. Psychiatry, 33:3, March/April, 1994

Swartz, "Tardive Psychopathology", Neuropsychobiology, 43:115-119, 1995.

Tirelli et al., "Differential Effects of Direct and Indirect Dopamine Agonists on the Induction of Gnawing in C57B1/6J Mice", J. Pharmacol Exp. Ther., 273:7-15, 1995.

Trube, et al., "Dextromethorphan: Cellular Effects Reducing Neuronal Hyperactivity" Epilepsia. 35:5 S62-S67, 1994

Tsai, et al., "Markers of Glutamatergic Neurotransmission and Oxidative Stress Associated with Tardive Dyskinesia", Am J. Psychiatry 155:9, September, 1998.

Vale et al., "Amantadine for Dyskinesia Tarda", New Eng. J. Med., 284:673, 1971.

Van-Rekum et al., "N of 1 Study: Amantadine for the Amotivational Syndrome in a Patient with Traumatic Brain Injury", Brian Inj. 9:49-53, 1995.

Waddington et al., "Cognitive Dysfunction in Chronic Schizophrenia Followed Prospectively Over 10 Years and Its Longitudinal Relationship to the Emergence of Tardive Dyskinesia", Psychol Med, 26:681-688, 1996.

Wenk et al., "MK-801, Memantine and Amantadine Show Neuroprotective Activity in the Nucleus Basalis Magnocellularis", Eur. J. Pharmacol, 293:267-270, 1995.

Wilde, et al., "Acamprosate", Adis Drug Evaluation, 53:1038-1053, June, 1997.

Yassa, et al., "Plasma Magnesium in Chronic Schizophrenia", Int. Pharmacopsychiat. 14:57-64 (1979)

Ziemann, et al., "Decreased Motor Inhibition in Tourette's Disorder: Evidence From Transcranial Magnetic Stimulation", Am J Psychiatry, 154:1277-1284, 1997.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.